Measuring the thickness of the microvascular glycocalyx, and make a comparement between lacunar stroke patients and healthy controls.We also compare glycocalyx between patients with and without concomitant silent signs of cSVD on brain MRI.
ID
Source
Brief title
Condition
- Central nervous system vascular disorders
- Vascular disorders NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Registration of baseline characteristics (age, gender, weight, length,
medication, cardiovascular risk profile, brain MRI)
Venous blood sampling for measuring of glucose, cholesterol, kreatinin, and CRP.
Measurement of the sublingual glycocalyx, non-invasively using sidestream dark
field imaging.
We will compare glycocalyx thickness between patients and controls, and between
patients with and without silent lesions.
Predictors of glycocalyx thickness will be analysed using regression analyses.
Secondary outcome
nvt
Background summary
A lacunar infarct is caused by an arteriopathy of small perforating brain
arteries, which is called cerebral small vessel disease (cSVD). cSVD can cause
a symptomatic lacunar stroke, but it can also cause "silent" lacunar infarcts,
white matter lesions and microbleeds. It is hypothesized that endothelial
dysfunction plays an important role in the pathogenesis of cSVD.
Glycocalyx is a thin layer at the inside of the endothelium in blood vessels.
Over the past decade, inside has been gained into the role of the glycoclayx
in vascular hemostasis. The glycocalyx acts as a protectionlayer between the
endothelium and flowing blood. Disturbance of the glycocalyx could be a cause
of endothelial dysfunction. Thus it could be that the glycocalyx is a factor in
the pathogenesis of cSVD.
Glycocalyx can not be measured in cerebral small vessels. However, there is
some evidence that cSVD parallels a systemic small vessel endotheliopathy. The
systemic microvascular glycocalyx can be measured in a quite simple way and
non-invasively: sublingual.
We hypothesize that the sublingual measured systemic microvascular glycocalyx
is thinner in patients with cSVD.
Study objective
Measuring the thickness of the microvascular glycocalyx, and make a comparement
between lacunar stroke patients and healthy controls.
We also compare glycocalyx between patients with and without concomitant silent
signs of cSVD on brain MRI.
Study design
observational case-control study
Study burden and risks
All participants will give informed consent.
Participants will come after an overnight fast. The whole procedure including
the measurement of glycocalyx will take 30 minutes. A venous blood sample will
be taken, which has only minimal risk. The measurement of glycocalyx is
non-invasively and without any risk.
postbus 5800
6202 AZ Maastricht
NL
postbus 5800
6202 AZ Maastricht
NL
Listed location countries
Age
Inclusion criteria
patients: first-ever lacunar stroke in the last 2 years, age 50-85 years
healthy controls: age 50-85 years, without major co-mobidity
Exclusion criteria
patients: carotid stenosis, cardioembolic source, diabetes, coronary heart disease, major co-morbidity
healthy controls: hypertension, diabetes, cardiovascular disease (TIA/stroke/coronary heart disease), use of cardiovascular medicine, silent signs of cSVD on (former) brain MRI
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL36504.068.11 |